Which has higher earnings & valuation, TECH or RGEN?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.32 $181.86M $1.15 62.89 Repligen $738.26M 13.85 $48.89M $0.73 248.12

Is TECH or RGEN more profitable?

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% Repligen 5.29% 5.30% 3.79%

Does the media prefer TECH or RGEN?

In the previous week, Bio-Techne had 4 more articles in the media than Repligen. MarketBeat recorded 15 mentions for Bio-Techne and 11 mentions for Repligen. Repligen's average media sentiment score of 1.38 beat Bio-Techne's score of 1.31 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or TECH?

In the previous week, Agilent Technologies had 13 more articles in the media than Bio-Techne. MarketBeat recorded 28 mentions for Agilent Technologies and 15 mentions for Bio-Techne. Agilent Technologies' average media sentiment score of 1.32 beat Bio-Techne's score of 1.31 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 22 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECH or BIO?

In the previous week, Bio-Techne had 11 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 15 mentions for Bio-Techne and 4 mentions for Bio-Rad Laboratories. Bio-Techne's average media sentiment score of 1.31 beat Bio-Rad Laboratories' score of 0.72 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRL or TECH?

In the previous week, Bio-Techne had 5 more articles in the media than Charles River Laboratories International. MarketBeat recorded 15 mentions for Bio-Techne and 10 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.31 beat Charles River Laboratories International's score of 0.45 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, DHR or TECH?

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Danaher $24.57B 6.28 $3.61B $5.63 38.97 Bio-Techne $1.22B 9.32 $181.86M $1.15 62.89

Is DHR or TECH more profitable?

Danaher has a net margin of 15.95% compared to Bio-Techne's net margin of 14.97%. Bio-Techne's return on equity of 13.23% beat Danaher's return on equity. Company Net Margins Return on Equity Return on Assets Danaher 15.95% 11.04% 6.81% Bio-Techne 14.97% 13.23% 10.61%

Does the media refer more to DHR or TECH?

In the previous week, Danaher had 95 more articles in the media than Bio-Techne. MarketBeat recorded 110 mentions for Danaher and 15 mentions for Bio-Techne. Danaher's average media sentiment score of 1.74 beat Bio-Techne's score of 1.31 indicating that Danaher is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Danaher 109 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bio-Techne 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bio-Techne (TECH) Competitors

$72.32 +0.04 (+0.06%)

As of 08/21/2026 04:00 PM Eastern

Compare

TECH vs. RGEN, A, BIO, CRL, and DHR

Should you buy Bio-Techne stock or one of its competitors? Bio-Techne's main competitors and comparable companies include Repligen (RGEN), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), and Danaher (DHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bio-Techne compare to Repligen?

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

98.9% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Repligen	5.29%	5.30%	3.79%

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89
Repligen	$738.26M	13.85	$48.89M	$0.73	248.12

Bio-Techne has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Repligen has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, Bio-Techne had 4 more articles in the media than Repligen. MarketBeat recorded 15 mentions for Bio-Techne and 11 mentions for Repligen. Repligen's average media sentiment score of 1.38 beat Bio-Techne's score of 1.31 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne presently has a consensus price target of $68.92, suggesting a potential downside of 4.70%. Repligen has a consensus price target of $166.43, suggesting a potential downside of 8.12%. Given Bio-Techne's higher possible upside, equities analysts clearly believe Bio-Techne is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Bio-Techne beats Repligen on 11 of the 17 factors compared between the two stocks.

How does Bio-Techne compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Agilent Technologies had 13 more articles in the media than Bio-Techne. MarketBeat recorded 28 mentions for Agilent Technologies and 15 mentions for Bio-Techne. Agilent Technologies' average media sentiment score of 1.32 beat Bio-Techne's score of 1.31 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	22 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.6%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.47	$1.30B	$4.98	31.98
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89

98.9% of Bio-Techne shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agilent Technologies has a net margin of 19.55% compared to Bio-Techne's net margin of 14.97%. Agilent Technologies' return on equity of 24.33% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Bio-Techne	14.97%	13.23%	10.61%

Agilent Technologies presently has a consensus target price of $160.24, suggesting a potential upside of 0.62%. Bio-Techne has a consensus target price of $68.92, suggesting a potential downside of 4.70%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Summary

Agilent Technologies beats Bio-Techne on 15 of the 20 factors compared between the two stocks.

How does Bio-Techne compare to Bio-Rad Laboratories?

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89
Bio-Rad Laboratories	$2.58B	3.95	$759.90M	$8.25	46.25

Bio-Techne presently has a consensus price target of $68.92, indicating a potential downside of 4.70%. Bio-Rad Laboratories has a consensus price target of $343.33, indicating a potential downside of 10.02%. Given Bio-Techne's higher probable upside, research analysts clearly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

98.9% of Bio-Techne shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bio-Techne has a net margin of 14.97% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Techne's return on equity of 13.23% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Bio-Techne has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

In the previous week, Bio-Techne had 11 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 15 mentions for Bio-Techne and 4 mentions for Bio-Rad Laboratories. Bio-Techne's average media sentiment score of 1.31 beat Bio-Rad Laboratories' score of 0.72 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Bio-Rad Laboratories on 11 of the 16 factors compared between the two stocks.

How does Bio-Techne compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bio-Techne has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.51	-$144.34M	-$4.85	N/A
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89

Charles River Laboratories International has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Bio-Techne has a net margin of 14.97% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Bio-Techne	14.97%	13.23%	10.61%

In the previous week, Bio-Techne had 5 more articles in the media than Charles River Laboratories International. MarketBeat recorded 15 mentions for Bio-Techne and 10 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.31 beat Charles River Laboratories International's score of 0.45 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Techne	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International presently has a consensus target price of $255.65, indicating a potential downside of 13.41%. Bio-Techne has a consensus target price of $68.92, indicating a potential downside of 4.70%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Summary

Bio-Techne beats Charles River Laboratories International on 10 of the 15 factors compared between the two stocks.

How does Bio-Techne compare to Danaher?

Danaher (NYSE:DHR) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.7%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Danaher pays out 28.4% of its earnings in the form of a dividend. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has increased its dividend for 2 consecutive years. Danaher is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Danaher has a net margin of 15.95% compared to Bio-Techne's net margin of 14.97%. Bio-Techne's return on equity of 13.23% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	15.95%	11.04%	6.81%
Bio-Techne	14.97%	13.23%	10.61%

79.1% of Danaher shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 10.8% of Danaher shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Danaher had 95 more articles in the media than Bio-Techne. MarketBeat recorded 110 mentions for Danaher and 15 mentions for Bio-Techne. Danaher's average media sentiment score of 1.74 beat Bio-Techne's score of 1.31 indicating that Danaher is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	109 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bio-Techne	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Danaher has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Danaher presently has a consensus target price of $228.91, indicating a potential upside of 4.33%. Bio-Techne has a consensus target price of $68.92, indicating a potential downside of 4.70%. Given Danaher's stronger consensus rating and higher probable upside, equities research analysts plainly believe Danaher is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.84
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.57B	6.28	$3.61B	$5.63	38.97
Bio-Techne	$1.22B	9.32	$181.86M	$1.15	62.89

Summary

Danaher beats Bio-Techne on 13 of the 20 factors compared between the two stocks.

Get Bio-Techne News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECH vs. The Competition

Export

Metric	Bio-Techne	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.32B	$10.24B	$7.37B	$12.85B
Dividend Yield	0.44%	1.46%	2.53%	11.08%
P/E Ratio	62.89	61.54	272.88	24.24
Price / Sales	9.32	110.30	618.96	99.81
Price / Cash	30.81	27.04	78.62	53.99
Price / Book	5.37	37.34	13.05	6.20
Net Income	$181.86M	$56.67B	$3.47B	$348.59M
7 Day Performance	-0.11%	5.24%	2.09%	0.08%
1 Month Performance	0.77%	9.02%	6.64%	3.88%
1 Year Performance	26.68%	24.45%	25.02%	16.98%

Bio-Techne Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECH Bio-Techne	3.2489 of 5 stars	$72.32 +0.1%	$68.92 -4.7%	+26.7%	$11.32B	$1.22B	62.89	3,100	News Coverage Analyst Forecast
RGEN Repligen	3.3573 of 5 stars	$169.04 +1.3%	$166.43 -1.5%	+45.1%	$9.42B	$738.26M	231.56	2,000	Positive News
A Agilent Technologies	4.5014 of 5 stars	$148.65 +0.1%	$160.24 +7.8%	+31.1%	$41.95B	$6.95B	29.85	18,100	News Coverage Positive News Upcoming Earnings
BIO Bio-Rad Laboratories	1.9026 of 5 stars	$355.06 -0.3%	$343.33 -3.3%	+25.9%	$9.53B	$2.58B	43.04	7,450	Gap Up
CRL Charles River Laboratories International	1.8661 of 5 stars	$286.44 +2.3%	$255.65 -10.8%	+82.7%	$13.37B	$4.02B	N/A	19,700	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECH) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Competitors

TECH vs. RGEN, A, BIO, CRL, and DHR

How does Bio-Techne compare to Repligen?

Summary

How does Bio-Techne compare to Agilent Technologies?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Summary

How does Bio-Techne compare to Danaher?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Competitors

TECH vs. RGEN, A, BIO, CRL, and DHR

How does Bio-Techne compare to Repligen?

Do insiders & institutionals believe in TECH or RGEN?

Is TECH or RGEN more profitable?

Which has higher earnings & valuation, TECH or RGEN?

Which has more risk and volatility, TECH or RGEN?

Does the media prefer TECH or RGEN?

Do analysts recommend TECH or RGEN?

Summary

How does Bio-Techne compare to Agilent Technologies?

Does the media prefer A or TECH?

Which has more risk and volatility, A or TECH?

Is A or TECH a better dividend stock?

Which has stronger valuation and earnings, A or TECH?

Do institutionals and insiders believe in A or TECH?

Is A or TECH more profitable?

Do analysts recommend A or TECH?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Which has higher valuation and earnings, TECH or BIO?

Do analysts prefer TECH or BIO?

Do institutionals and insiders have more ownership in TECH or BIO?

Is TECH or BIO more profitable?

Which has more risk and volatility, TECH or BIO?

Does the media prefer TECH or BIO?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Do institutionals & insiders believe in CRL or TECH?

Which has better earnings & valuation, CRL or TECH?

Which has more risk & volatility, CRL or TECH?

Is CRL or TECH more profitable?

Does the media refer more to CRL or TECH?

Do analysts prefer CRL or TECH?

Summary

How does Bio-Techne compare to Danaher?

Is DHR or TECH a better dividend stock?

Is DHR or TECH more profitable?

Do insiders and institutionals have more ownership in DHR or TECH?

Does the media refer more to DHR or TECH?

Which has more volatility & risk, DHR or TECH?

Do analysts recommend DHR or TECH?

Which has better earnings and valuation, DHR or TECH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools